Programmed cell death protein 1 (PD-1) [12, 14, 16] (PD-1 [1, 14, 16])

Programmed cell death protein 1 (PD-1) is a cell surface receptor belonging to the immunoglobulin superfamily, primarily expressed on activated T cells, B cells, and myeloid cells [14, 16]. It serves as a critical immune checkpoint that down-regulates the immune response and promotes self-tolerance by suppressing T-cell inflammatory activity [12, 15]. Under normal physiological conditions, PD-1 binds to its ligands, PD-L1 and PD-L2, to prevent overactive immune responses and autoimmune diseases [14, 15]. However, many tumors exploit this pathway by overexpressing PD-L1, which binds to PD-1 on infiltrating T cells and induces a state of exhaustion, allowing the cancer to evade immune detection and destruction [17, 18].\n\nZimberelimab is a fully human monoclonal antibody designed to specifically bind to PD-1 and block its interaction with these ligands [1, 2]. By inhibiting this signaling axis, zimberelimab restores the effector function of cytotoxic T cells, enabling them to recognize and eliminate tumor cells [3, 4]. This therapeutic approach has demonstrated significant efficacy across various malignancies, including cervical cancer and non-small cell lung cancer [1, 7]. While effective in oncology, modulating PD-1 can lead to immune-related adverse events due to the systemic loss of immune inhibition [2, 15].

Other names

PDCD1 [12, 14, 16]CD279 [14, 16]SLEB2 [14, 20]hPD-1 [12, 16]hPD-l [14]Protein PD-1 [12, 16]

Zimberelimab is a PD-1 inhibitor that binds to the PD-1 receptor on T cells, blocking its interaction with the ligands PD-L1 and PD-L2 [1, 2]. This blockade prevents the inhibitory signaling that normally suppresses T-cell activity, thereby restoring the immune system's ability to recognize and attack cancer cells [3, 4].